Skip to main content

Advertisement

SpringerLink
Log in

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy. However, the association between SVR and viral kinetics earlier than week 4 after initiation of therapy remains unclear. Thus, we evaluated the SVR prediction ability of baseline factors and reduced hepatitis C virus (HCV) RNA levels at week 1 after the initiation of TVR-based therapy in Japanese genotype-1b chronic hepatitis C (CHC) patients.

Methods

A total of 156 Japanese CHC patients received a 24-week regimen of TVR-based therapy. Baseline factors and reduction in HCV RNA levels at weeks 1 and 4 after the initiation of therapy were analyzed for SVR prediction.

Results

Multiple logistic regression analysis for SVR in TVR-based therapy identified the IL28B TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1, RVR, and treatment-naïve/relapse. Whereas the SVR rate was higher than 90 % regardless of the reduction in HCV RNA levels at week 1 in patients with the TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1 was the strongest predictor of SVR in patients with the non-TT genotype, as determined by multiple logistic regression analysis (P = 0.0043).

Conclusions

The IL28B TT genotype is the most important baseline factor for predicting SVR, and a ≥4.7 log10IU/mL reduction in HCV RNA at week 1 is a useful very early on-treatment predictor of SVR, especially in the non-TT genotype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ghany MG, Nelson DR, Strader DB, American Association for Study of Liver Diseases, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

    Article  PubMed Central  PubMed  Google Scholar 

  2. McHutchison JG, Everson GT, Gordon SC, PROVE1 Study Team, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.

    Article  CAS  PubMed  Google Scholar 

  3. Hézode C, Forestier N, Dusheiko G, PROVE2 Study Team, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–50.

    Article  PubMed  Google Scholar 

  4. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.

    Article  CAS  PubMed  Google Scholar 

  5. McHutchison JG, Manns MP, Muir AJ, PROVE3 Study Team, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–303.

    Article  CAS  PubMed  Google Scholar 

  6. Zeuzem S, Andreone P, Pol S, REALIZE Study Team, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.

    Article  CAS  PubMed  Google Scholar 

  7. Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204:84–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54:1538–46.

    Article  CAS  PubMed  Google Scholar 

  9. Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol. 2012;84:1097–105.

    Article  CAS  PubMed  Google Scholar 

  10. Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–12.

    Article  CAS  PubMed  Google Scholar 

  12. Muir AJ. IL28B in the era of direct-acting antivirals for hepatitis C. J Clin Gastroenterol. 2013;47:222–7.

    Article  CAS  PubMed  Google Scholar 

  13. Pol S, Aerssens J, Zeuzem S, et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol. 2013;58:883–9.

    Article  CAS  PubMed  Google Scholar 

  14. Akuta N, Suzuki F, Fukushima T, et al. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with HCV genotype 1. J Clin Microbiol. 2013;51:2862–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Tsubota A, Shimada N, Atsukawa M, et al. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with HCV genotype 1b. J Gastroenterol Hepatol. 2013 (Epub ahead of print).

  16. Shimada N, Tsubota A, Atsukawa M, et al. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. J Med Virol. 2013 (Epub ahead of print).

  17. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.

    Article  CAS  PubMed  Google Scholar 

  18. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.

    Article  CAS  PubMed  Google Scholar 

  19. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.

    Article  CAS  PubMed  Google Scholar 

  20. Tsubota A, Shimada N, Yoshizawa K, et al. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Int. 2012;32:826–36.

    Article  CAS  PubMed  Google Scholar 

  21. Toyoda H, Kumada T, Shimada N, et al. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. J Med Virol. 2013;85:65–70.

    Article  CAS  PubMed  Google Scholar 

  22. Toyoda H, Kumada T, Shimada N, et al. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis. 2012;12:324.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Yoshizawa K, Abe H, Aida Y, et al. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. J Med Virol. 2013;85:1180–90.

    Article  CAS  PubMed  Google Scholar 

  24. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52:421–9.

    Article  CAS  PubMed  Google Scholar 

  25. Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the management of hepatitis C virus infection: first edition, May 2012. The Japan Society of Hepatology. Hepatol Res. 2013;2013(43):1–34.

    Article  Google Scholar 

  27. Jacobson IM, McHutchison JG, Dusheiko G, ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

    Article  CAS  PubMed  Google Scholar 

  28. McHutchison JG, Lawitz EJ, Shiffman ML, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93.

    Article  CAS  PubMed  Google Scholar 

  29. Sherman KE, Flamm SL, Afdhal NH, ILLUMINATE Study Team, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–24.

    Article  CAS  PubMed  Google Scholar 

  30. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20.

    Article  Google Scholar 

  31. Simmonds P, Mellor J, Sakuldamrongpanich T, et al. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol. 1996;77:3013–24.

    Article  PubMed  Google Scholar 

  32. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372–80.

    Article  CAS  PubMed  Google Scholar 

  33. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403–10.

    Article  CAS  PubMed  Google Scholar 

  34. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;11(334):77–81.

    Article  Google Scholar 

  35. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221–9.

    Article  CAS  PubMed  Google Scholar 

  36. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2013 (Epub ahead of print).

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo, Chiba, 270-0034, Japan

    Noritomo Shimada & Keizo Kato

  2. Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu, 503-8502, Japan

    Hidenori Toyoda & Takashi Kumada

  3. Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba, 277-8567, Japan

    Akihito Tsubota

  4. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan

    Tatsuya Ide & Michio Sata

  5. Department of Hepatology, Kagawa Prefectural Central Hospital, 5-4-16 Bancho, Takamatsu, Kagawa, 760-8557, Japan

    Koichi Takaguchi

  6. Department of Life Cycle Management, Roche Diagnostics K.K, 2-6-1 Shiba, Minato-ku, Tokyo, 105-0014, Japan

    Masaki Kondoh & Kazuhiro Matsuyama

Authors
  1. Noritomo Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hidenori Toyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akihito Tsubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuya Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koichi Takaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keizo Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masaki Kondoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuhiro Matsuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takashi Kumada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michio Sata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noritomo Shimada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimada, N., Toyoda, H., Tsubota, A. et al. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol 49, 1485–1494 (2014). https://doi.org/10.1007/s00535-013-0918-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-013-0918-7

Keywords

Search

Navigation